Key Highlights
- Rachael Brake, PhD, joins Zephyr AI as Chief Scientific Officer, bringing extensive experience in oncology and precision medicine.
- Brake’s appointment strengthens Zephyr’s mission to democratize precision medicine through AI, addressing unmet patient needs.
- Former roles include leadership positions at Corbus Pharmaceuticals and Takeda Oncology, emphasizing a strong background in research and development.
Source: Business Wire
Notable Quotes
- “Rachael’s mission-driven desire to simplify the complexities of personalized medicine is perfectly aligned with Zephyr’s commitment to address patients’ unmet needs and optimize outcomes.” – Jeff Sherman, Co-Founder, Interim CEO, and CTO at Zephyr AI
- “AI holds great potential to not only inform our treatment strategies; I believe it will also mobilize our industry to unlock novel approaches to tackling cancer and cardiometabolic disease.” – Rachael Brake, PhD, Chief Scientific Officer at Zephyr AI
SoHC's Take
Zephyr AI’s latest move to appoint Rachael Brake, PhD, as its Chief Scientific Officer underscores the company’s dedication to spearheading advancements in precision medicine through artificial intelligence. Brake’s illustrious career in oncology and precision medicine, marked by her roles at Corbus Pharmaceuticals and Takeda Oncology, positions her as a formidable leader in Zephyr AI’s quest to revolutionize patient care. This strategic appointment aligns with Zephyr’s mission to utilize AI for generating novel insights and developing tools that not only support patient and provider decisions but also propel further research into combating cancer and cardiometabolic diseases. With the world’s most comprehensive healthcare dataset at their disposal, Zephyr AI and its team of experts are poised to deliver transformational outcomes in the healthcare sector.
